<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267863</url>
  </required_header>
  <id_info>
    <org_study_id>253-HEM1-01</org_study_id>
    <nct_id>NCT02267863</nct_id>
  </id_info>
  <brief_title>A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS</brief_title>
  <official_title>A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptose Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptose Biosciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety and effectiveness of APTO-253 for the&#xD;
      treatment of patients with the condition of acute myelogenous leukemia (AML) or&#xD;
      myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no&#xD;
      longer effective, or can no longer be administered safely or poses a risk for your general&#xD;
      well being.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, Phase Ia/b dose escalation study of safety,&#xD;
      pharmacodynamics, and pharmacokinetics of APTO-253 in ascending cohorts (3+3 design) to&#xD;
      determine the MTD or recommended dose in patients with relapsed or refractory acute&#xD;
      myelogenous leukemia (AML) or high-risk MDS patients. This is to be followed by a cohort&#xD;
      expansion phase at the MTD or recommended dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events of APTO-253</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>To determine the safety and tolerability of APTO-253 by assessing treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose and dose limiting toxicities</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of APTO-253 when given on days 1, 8, 15, and 22 of each 28-day cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish recommended dose for future development of APTO-253</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>To establish the dose of APTO-253 recommended for future development of APTO-253 for patients with specific types of hematologic malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including maximum plasma concentration (Cmax)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including minimum plasma concentration (Cmin)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including minimum plasma concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including Area Under the Curve (AUC)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including Area Under the Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including volume of distribution</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including clearance</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including serum half-life</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Pharmacokinetic variables including serum half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess for any evidence of antitumor activity of APTO-253 by hematologic and bone marrow evaluations in acute leukemia and MDS.</measure>
    <time_frame>Average 2 Cycles (8 weeks)</time_frame>
    <description>To observe patients for any evidence of antitumor activity of APTO-253 by hematologic and bone marrow evaluations in acute leukemia and MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the ability of APTO-253 to alter the expression of pharmacodynamic biomarkers of drug effect.</measure>
    <time_frame>Average 2 Cycles (8 weeks)</time_frame>
    <description>To determine the ability of APTO-253 to alter the expression of pharmacodynamic biomarkers of drug effect.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myelogenous Leukemia in Relapse</condition>
  <condition>Acute Myelogenous Leukemia, Relapsed, Adult</condition>
  <condition>Acute Myelogenous Leukemia, Adult</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>High Risk Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>Dose Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APTO-253</intervention_name>
    <description>APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.</description>
    <arm_group_label>Dose Escalation and Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients â‰¥18 years old&#xD;
&#xD;
          -  Life expectancy of at least 2 months&#xD;
&#xD;
          -  Off previous cancer therapy for at least 14 days, or 5 half-lives for noncytotoxic&#xD;
             agents prior to first study treatment administration&#xD;
&#xD;
          -  Patients must have a calculated creatinine clearance &gt;60 mL/min&#xD;
&#xD;
          -  Acceptable hematologic, renal and liver functions and coagulation status parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with GVHD requiring systemic immunosuppressive therapy&#xD;
&#xD;
          -  Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and&#xD;
             clinical significant disease related metabolic disorder&#xD;
&#xD;
          -  Clinically significant intravascular coagulation&#xD;
&#xD;
          -  Treatment with other investigational drugs within 14 days prior to first study&#xD;
             treatment administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Bejar, MD., PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Aptose Biosciences Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashleigh Campillo</last_name>
    <phone>858-333-6118</phone>
    <email>acampillo@aptose.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor Montalvo Lugo</last_name>
    <phone>858-926-2740</phone>
    <email>VMontalvo@aptose.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesika Reiner, MPH</last_name>
      <phone>858-822-5364</phone>
      <email>jreiner@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Tzachanis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Blake Johnson</last_name>
      <phone>714-456-3476</phone>
      <email>blakej@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deepa Jeyakumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University; Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gleason, MLS</last_name>
      <phone>404-778-4334</phone>
      <email>shannon.gleason@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Victor Neirinckx</last_name>
      <phone>404-778-4994</phone>
      <email>victor.d.neirinckx@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Martha Arellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Cancer Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Duyck</last_name>
      <phone>406-238-6290</phone>
      <email>heather.duyck@sclhealth.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester; Wilmot Cancer Institute Clinical Trials Office</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14643</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Misch</last_name>
      <phone>585-275-5345</phone>
      <email>Haley_Misch@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen ODwyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Prisma Health, Institute for Translational Oncology Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Roemmich</last_name>
      <phone>864-455-3294</phone>
      <email>jill.roemmich@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Cull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Jones</last_name>
      <phone>214-820-1970</phone>
      <email>LISA.JONES2@BSWHEALTH.ORG</email>
    </contact>
    <investigator>
      <last_name>Moshe Y. Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Thomas, RN, BSN</last_name>
      <phone>713-745-4642</phone>
      <email>RMThomas3@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Kelly, RN</last_name>
      <phone>713-794-4656</phone>
      <email>MAKelly1@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Maro Ohanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.aptose.com/clinical-trials/apto-253</url>
    <description>Aptose Biosciences</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 3, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Aptose</keyword>
  <keyword>APTO-253</keyword>
  <keyword>Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

